Periodic trends in geographical variation of prostate cancer incidence and mortality in Finland between 1985 and 2019

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Platz EA, Giovannucci E. Cancer epidemiology and prevention. Prostate cancer. New York, NY: Oxford University Press; 2006. p. 1128–1150.
   Google Scholar
• Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–67.
   PubMed Web of Science ®Google Scholar
• Age-standardised incidence rate of prostate cancer per 100,000 in Finland 1953–2019: Cancer society of Finland; Finnish Cancer Registry. 2021; [cited 2021 Aug 3]. Available from: https://cancerregistry.fi/statistics/cancer-statistics/.
   Google Scholar
• Age-standardised mortality rate of prostate cancer per 100,000 in Finland 1953–2019: Cancer society of Finland; Finnish Cancer Registry. 2021; [cited 2021 August 3]. Available from: https://cancerregistry.fi/statistics/cancer-statistics/.
   Google Scholar
• Keskimaki I, Tynkkynen LK, Reissell E, et al. Finland: health system review. Health Syst Transit. 2019;21(2):1–166.
   PubMedGoogle Scholar
• Mäkinen T, Tammela TL, Stenman UH, et al. Second round results of the finnish population-based prostate cancer screening trial. Clin Cancer Res. 2004;10(7):2231–2236.
   PubMed Web of Science ®Google Scholar
• Kilpelainen TP, Pogodin-Hannolainen D, Kemppainen K, et al. Estimate of opportunistic prostate specific antigen testing in the finnish randomized study of screening for prostate cancer. J Urol. 2017;198(1):50–57.
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Jousilahti P, Kataja V, et al. Eturauhassyövän Käypä hoito-suositus; [cited 2022 Jun 14]. Available from: http://www.kaypahoito.fi2014.
   Google Scholar
• StatisticsFinland; [cited 2022 Jun 8]. Available from: https://www.stat.fi/artikkelit/2014/art_2014-12-08_002.html?s=0.
   Google Scholar
• Stattin P, Johansson R, Lodnert R, et al. Geographical variation in incidence of prostate cancer in Sweden. Scand J Urol Nephrol. 2005;39(5):372–379.
   PubMed Web of Science ®Google Scholar
• Seppä K, Malila N, Pitkäniemi J. Variation in cancer survival between hospital districts and within them in Finland. Acta Oncol. 2020;59(11):1316–1321.
   PubMed Web of Science ®Google Scholar
• Finnish Cancer Registry. Cancer screening in Finland: Finnish Cancer Registry. 2022; [cited 2022 Jun 16]. Available from: https://cancerregistry.fi/screening/.
   Google Scholar
• Leinonen MK, Miettinen J, Heikkinen S, et al. Quality measures of the population-based finnish cancer registry indicate sound data quality for solid malignant tumours. Eur J Cancer. 2017;77:31–39.
   PubMed Web of Science ®Google Scholar
• Statistics Finland. Statistical grouping of municipalities: Statistics Finland. 2022; [cited 2022 Jun 17]. Available from: https://www.stat.fi/meta/kas/til_kuntaryhmit_en.html.
   Google Scholar
• Seppä K, Rue H, Hakulinen T, et al. Estimating multilevel regional variation in excess mortality of cancer patients using integrated nested laplace approximation. Stat Med. 2019;38(5):778–791.
   PubMed Web of Science ®Google Scholar
• Draisma G, Etzioni R, Tsodikov A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–383.
   PubMedGoogle Scholar
• Wah W, Ahern S, Evans S, et al. Geospatial and temporal variation of prostate cancer incidence. Public Health. 2021;190:7–15.
   PubMed Web of Science ®Google Scholar
• Seikkula HA, Kaipia AJ, Rantanen ME, et al. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. Acta Oncol. 2017;56(7):971–977.
   PubMed Web of Science ®Google Scholar
• Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the european randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43–51.
   PubMed Web of Science ®Google Scholar
• Oliver SE, May MT, Gunnell D. International trends in prostate-cancer mortality in the ’PSA ERA’. Int J Cancer. 2001;92(6):893–898.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Ullman KE, Linskens EJ, et al. Therapies for clinically localized prostate cancer: a comparative effectiveness review. J Urol. 2021;205(4):967–976.
   PubMed Web of Science ®Google Scholar
• James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the ’docetaxel era’: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–1038.
   PubMed Web of Science ®Google Scholar
• Pokhrel A, Martikainen P, Pukkala E, et al. Education, survival and avoidable deaths in cancer patients in Finland. Br J Cancer. 2010;103(7):1109–1114.
   PubMed Web of Science ®Google Scholar
• Rapiti E, Fioretta G, Schaffar R, et al. Impact of socioeconomic status on prostate cancer diagnosis, treatment, and prognosis. Cancer. 2009;115(23):5556–5565.
   PubMed Web of Science ®Google Scholar
• Palo JU, Ulmanen I, Lukka M, et al. Genetic markers and population history: Finland revisited. Eur J Hum Genet. 2009;17(10):1336–1346.
   PubMed Web of Science ®Google Scholar
• Jousilahti P, Vartiainen E, Tuomilehto J, et al. Role of known risk factors in explaining the difference in the risk of coronary heart disease between Eastern and southwestern Finland. Ann Med. 1998;30(5):481–487.
   PubMed Web of Science ®Google Scholar
• Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer. 2010;46(17):3040–3052.
   PubMed Web of Science ®Google Scholar
• Auvinen A, Rietbergen JB, Denis LJ, et al. Prospective evaluation plan for randomised trials of prostate cancer screening. The international prostate cancer screening trial evaluation group. J Med Screen. 1996;3(2):97–104.
   PubMedGoogle Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer 2020; [cited 2022 Aug 6]. Available from: https://uroweb.org/guideline/prostate-cancer/.
   Google Scholar
• Statistics Finland: Cause of death data from Finland. 2008; [cited 2021 Aug 16]. Available from: https://www.stat.fi/til/ksyyt/2008/ksyyt_2008_2009-12-18_tie_001.html.
   Google Scholar
• Finnish Cancer Registry. 2021. [cited 2021 Aug 13]. Available from: https://cancerregistry.fi/statistics/cancer-statistics/.
   Google Scholar
• Statistics Finland. Quality description: Causes of death. 2020. Statistics Finland; 2020; [cited 2022 Jun 16]. Available from: https://www.stat.fi/til/ksyyt/2020/ksyyt_2020_2021-12-10_laa_001_en.html.
   Google Scholar